Merck KGaA's Stimuvax set to become 'gold standard' for locally-advanced non-small-cell lung cancer
Merck KGaA/Oncothyreon's Stimuvax vaccine has earned advisory firm Decision Resources' proprietary clinical 'gold standard' status in 2013 and 2018 for the treatment of locally-advanced non-small-cell lung cancer. Available data from Phase II clinical trials of Stimuvax have shown promising median overall survival and tumor response rates in patients when the drug is used as a maintenance therapy following chemo-radiotherapy.
"Interviewed oncologists are excited about Stimuvax' Phase IIb clinical trial results in a subset of patients with locally advanced disease, and they are hopeful that the findings will be supported by positive Phase III data, especially given that ongoing studies include patients who will have a lower tumor burden than those involved in the Phase IIb trial," stated Decision Resources analyst Janie Cox.
Oncologists' choices
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze